Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Streptomycin Sulfate

FDA-approved product (injectable, injection), marketed as Streptomycin Sulfate.

Registered studies
32
Lab records
63
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Streptomycin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chancroid
  • Granuloma inguinale
  • Infection
  • Pneumonia
  • Septicemic plague
  • Tuberculosis
  • Tularemia
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Streptomycins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GA01; WHO ATC A07AA04; WHO ATC A07AA54

Repurposing investigation

Streptomycin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA74.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli71.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae75.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis87.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 15 of 15 lab records
  • M. tuberculosis: measured active in 41 of 42 lab records
Open Streptomycin Sulfate in ChEMBL Registered studies below
Show the 63 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Streptomycin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease

    NCT00004689 · start 1991-01

    Registered record
    Registry ID
    NCT00004689
    Conditions
    Mycobacterium Avium-intracellulare Infection
    Interventions
    amithiozone; clarithromycin; ethambutol; rifampin; streptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1991-01
    Completion
    1998-09
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection
    Interventionamithiozone; clarithromycin; ethambutol; rifampin +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

    NCT00000796

    Registered record
    Registry ID
    NCT00000796
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Cycloserine; Ethionamide; Capreomycin sulfate; Aminosalicylic acid; Streptomycin sulfate; Ethambutol hydrochloride; Amikacin sulfate; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride; Levofloxacin; Rifampin; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-10
    Enrolment
    525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionCycloserine; Ethionamide; Capreomycin sulfate; Aminosalicylic acid +9 more
    PhaseNot applicable
    Registry statusCompleted